ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.480
-0.010 (-0.67%)
At close: Apr 28, 2026, 4:00 PM EDT
1.550
+0.070 (4.73%)
After-hours: Apr 28, 2026, 7:53 PM EDT
ProQR Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for ProQR Therapeutics stock have an average target of 6.80, with a low estimate of 4.00 and a high estimate of 9.00. The average target predicts an increase of 359.46% from the current stock price of 1.48.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ProQR Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +170.27% | Apr 9, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +170.27% | Nov 4, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +170.27% | Aug 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $8 | Buy | Reiterates | $8 | +440.54% | Jun 27, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $8 | Buy | Reiterates | $8 | +440.54% | Jun 27, 2025 |
Financial Forecast
Revenue This Year
13.67M
from 16.35M
Decreased by -16.39%
Revenue Next Year
15.57M
from 13.67M
Increased by 13.92%
EPS This Year
-0.50
from -0.40
EPS Next Year
-0.56
from -0.50
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 24.1M | 31.0M | ||||||
| Avg | 13.7M | 15.6M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 47.7% | 126.6% | ||||||
| Avg | -16.4% | 13.9% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.39 | -0.39 | |
| Avg | -0.50 | -0.56 | |
| Low | -0.55 | -0.76 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.